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Abstract
High-mobility group box 1 (HMGB1) is a DNA-binding protein that
also exhibits proinflammatory cytokine-like activity. HMGB1 is
passively released by necrotic cells and also is actively secreted by
immunostimulated macrophages, dendritic cells, and enterocytes.
Although circulating HMGB1 levels are increased relative to
healthy controls in patients with infections and severe sepsis,
plasma or serum HMGB1 concentrations do not discriminate reliably
between infected and uninfected critically ill patients. Nevertheless,
administration of drugs that block HMGB1 secretion or of anti-
HMGB1 neutralizing antibodies has been shown to ameliorate
organ dysfunction and/or improve survival in numerous animal
models of critical illness. Because HMGB1 tends to be released
relatively late in the inflammatory response (at least in animal
models of endotoxemia or sepsis), this protein is an attractive
target for the development of new therapeutic agents for the
treatment of patients with various forms of critical illness.
Introduction
Originally identified in the early 1960s [1], high-mobility group
(HMG) proteins have been isolated and characterized from a
wide variety of eukaryotic species, ranging from yeast to
humans [2]. Based on the presence of characteristic
functional  sequences, three HMG subgroups have been
identified [3-5]: the HMGB family, the HMGN family, and the
HMGA family. All HMG proteins bind DNA and are soluble in
5% perchloric acid [2]. HMG proteins all have an unusual
amino acid composition characterized by a high content of
charged amino acids and a high content of proline [3].
The HMGB family proteins, namely HMG box 1 (HMGB1)
(previously called HMG1) and HMGB2 (previously called
HMG2), have molecular masses of approximately 28 kDa and
share greater than 80% amino acid sequence identity [3,6].
The HMGB proteins bend DNA by virtue of a conserved
DNA-binding domain, the so-called HMG1 box [5]. Each
HMG1 box contains a string of 70 to 80 amino acid residues,
which is folded into a characteristic, twisted, L-shaped
structure [5,7]. HMGB1 facilitates the binding of several
regulatory protein complexes to DNA, particularly members of
the nuclear hormone-receptor family [8,9], V(D)J recombi-
nases [10], and the tumor suppressor proteins, p53 and p73
[11].
The cytokine-like role of high-mobility group box 1
In 1999, Wang and colleagues [12] identified HMGB1 as a
cytokine-like mediator of lipopolysaccharide (LPS)-induced
mortality in mice. Subsequently, these findings were extended
by Yang and colleagues [13], who showed that HMGB1 is
also a mediator of lethality in mice rendered septic by the
induction of polymicrobial bacterial peritonitis. Additional
studies documented that extracellular HMGB1 can promote
tumor necrosis factor (TNF) release from mononuclear cells
[14] and increase the permeability of Caco-2 monolayers [15].
One of the most interesting features of HMGB1 as a
cytokine-like mediator of inflammation is that this protein is
released much later in the inflammatory process than are the
classical ‘alarm-phase’ cytokines, such as TNF and interleukin
(IL)-1β. For example, in mice, injection of a bolus dose of LPS
elicits a monophasic spike in circulating TNF which peaks
within 60 to 90 minutes of the proinflammatory challenge and
is over within 4 hours [16]. The peak in IL-1β concentration
occurs somewhat later (that is, 4 to 6 hours after the injection
of LPS) [17]. In contrast, after mice are injected with LPS,
circulating levels of HMGB1 are not elevated until 16 hours
after the proinflammatory stimulus but remain elevated for
more than 30 hours [12]. Furthermore, treatment with
neutralizing anti-HMGB1 antibodies [12,13] or various
pharmacological agents that block HMGB1 secretion, such
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as nicotine [18] or ethyl pyruvate [19], is effective in preven-
ting LPS- or sepsis-induced lethality, even when therapy is
started 4 to 24 hours after the initiation of the disease process.
Because of the delayed kinetics for release, HMGB1 is a very
attractive drug target for acute, often lethal, syndromes such
as severe sepsis and hemorrhagic shock because the
‘treatment window’ for anti-HMGB1 therapies should be
longer than is the case for therapeutic agents directed at
more proximal mediators of the inflammatory cascade (for
example, TNF or IL-1β).
Passive release and active secretion of high-mobility
group box 1
Data obtained by Scaffidi and colleagues [20] supported the
view that HMGB1 is passively released by necrotic, but not
apoptotic, cells. This process may depend, at least in part,
on activation of the enzyme PARP (poly[ADP]-ribose poly-
merase), which is activated as a result of DNA damage and
which upon activation promotes translocation of HMGB1
from the nucleus to the cytosol [21]. In this fashion, the
release of HMGB1 from necrotic tissue damaged by trauma
or ischemia could serve as an endogenous ‘danger signal’
that alerts the immune system to the presence of injured cells
[22,23].
Recently, however, Jiang and colleagues [24] reported that
macrophages and Jurkat T cells passively release HMGB1
during the process of apoptosis. Similarly, Bell and
colleagues [25] reported that Jurkat cells, U937 human
monocytic cells, Panc1 (human pancreatic cancer) cells, and
HeLa cells all passively release HMGB1 when apoptosis is
induced by agents, such as staurosporine, etoposide, or
camptothecin. Furthermore, Qin and colleagues [26] showed
that incubating RAW 264.7 murine macrophage-like cells
with apoptotic or necrotic macrophages or apoptotic T
lymphocytes triggers the active secretion of HMGB1 by the
RAW 264.7 cells. Thus, it seems doubtful that passive
release of HMGB1 occurs only when cells die a necrotic
(rather than apoptotic) death. Also, it seems doubtful that only
necrotic cells are capable of eliciting HMGB1 secretion by
other (viable) macrophages.
HMGB1 is actively secreted by immunostimulated macro-
phages [12,27-29], natural killer cells [30], plasmacytoid
dendritic cells [31], pituicytes [32], and enterocytes [33]. As
with members of the IL-1 family of cytokines, the primary
amino acid sequence of HMGB1 lacks a signal peptide.
Accordingly, secretion of HMGB1 by macrophages or
monocytes presumably occurs via a nonclassical secretory
pathway. Indeed, when monocytes are activated by exposure
to LPS, HMGB1 relocalizes from the nucleus into
cytoplasmic organelles that belong to the endolysosomal
compartment [28]. Gardella and colleagues [28] reported
that 65% of HMGB1 is confined to the nucleus in resting
monocytes but that only 26% of HMGB1 is nuclear and 74%
is associated with cytoplasmic organelles in LPS-stimulated
monocytes. In activated monocytes, the transfer of HMGB1
from the nucleus to the cytoplasm is mediated by
hyperacetylation of critical lysine clusters that are
components of nuclear localization signals [29]. This
acetylation prevents HMGB1 from interacting with the
nuclear-importer protein complex, so re-entry to the nucleus
is blocked. Acetylated, cytosolic HMGB1 subsequently
migrates to cytoplasmic secretory vesicles. Currently, it is not
known how cellular activation leads to acetylation of HMGB1.
Epithelial cells, including enterocytes, also secrete HMGB1
following immune stimulation. Kuniyasu and colleagues [34]
recently reported that WiDr human colon cancer cells
constitutively release HMGB1 into culture supernatants. In
contrast, Liu and colleagues [33] observed only very low
levels of HMGB1 in the media of unstimulated Caco-2
human transformed enterocyte-like cells. However, following
stimulation of the cells with a mixture of TNF, IL-1β, and
interferon-gamma [IFN-γ]), there was a large increase in the
amount of HMGB1 released into the culture media. Liu and
colleagues [33] also showed that incubating Caco-2 cells
with the synthetic Toll-like receptor (TLR) 2 ligand, FSL-1, or
the TLR5 ligand, flagellin, caused a large increase in the
amount of HMGB1 released into the media. Interestingly, the
TLR4 agonist, LPS, failed to stimulate HGMB1 secretion by
Caco-2 cells.
Data obtained by Gardella and colleagues [28] support the
notion that the secretion of HMGB1 by stimulated monocytes
occurs when secretory lysosomes undergo exocytosis. In
contrast, secretion of HMGB1 from Caco-2 cells apparently
depends on the release of exosomes into the extracellular
environment upon exocytic fusion of multivesicular endo-
somes with the cell surface [33]. Exosomes are 30- to 90-nm
membrane-bound vesicles that are secreted by numerous cell
types, including reticulocytes [35], platelets [36], B lympho-
cytes [37], dendritic cells [38], and epithelial cells [39]. Exo-
somes are formed when multivesical bodies in the cytoplasm
fuse with the plasma membrane, releasing the vesicles into
the extracellular compartment [40].
Regulation of high-mobility group box 1 mRNA
expression
HMGB1 is expressed in virtually all nucleated cells. In
general, the HMGB1 gene appears to be tightly regulated,
being expressed at a basal level in most cells and tissues. In
proliferating tissues and actively dividing cells, there is a
slight increase in expression level (approximately twofold)
[41,42]. Expression of HMGB1 increases by about the same
extent when estrogen-responsive breast cancer cells are
treated with estrogen [43] or synchronized Chinese hamster
ovary cells progress from the G1 to the S phase [44].
Transcription of the human HMGB1 gene starts at a major
site located 57 nucleotides upstream from the first exon–
intron boundary [45]. The core promoter of the humanPage 3 of 8
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HMGB1 gene lacks a TATA box and is located within the
-219 to +154 region. Immediately upstream of the core
promoter, there is a silencer element that contains a putative
growth factor independence-1 (GFI-1)-binding site. Since
GFI-1 is a known repressor [46], it is possible that GFI-1
binds to this site and represses the expression of HMGB1.
Constitutive activity of this repressor may be important for
maintaining HMGB1 expression at basal levels in most cells.
Intron 1 is highly conserved between the human and the
mouse HMGB1 genes. The region of intron 1 between +155
to +2061 contains enhancer activity, and the most potent
enhancer elements are located between +1043 and +1429.
Within this region of intron 1, there are several binding sites
of putative Sp1, activator protein (AP) 1, AP4, and upstream
stimulatory factor. Sp1, in particular, is known to enhance the
expression of genes with TATA-less core promoters [47,48]
and is known to be crucial for the transcriptional regulation of
IL-10 secretion by LPS-stimulated macrophages [49].
Furthermore, signaling via members of the AP1 family of
transcription factors is known to be important in the
transcriptional regulation of a number of genes, such as heme
oxygenase-1 [50,51] and IL-18 [52], in LPS- and/or IFN-γ-
stimulated macrophages.
According to Kalinina and colleagues [53], steady-state levels
of HMGB1 mRNA are increased in THP-1 human
promonocyte-like cells stimulated with IFN-γ or TNF. These
authors reported that TNF- or IFN-γ-induced upregulation of
HMGB1 mRNA expression is not affected in THP-1 cells by
pharmacological inhibition of extracellular signal-regulated
kinase (ERK) 1/ERK2 mitogen-activated protein kinase
(MAPK)- or PKC (protein kinase C)-dependent signaling but
is inhibited by treating the cells with wortmannin, an inhibitor
of PI3K (phosphatidyl inositol-3-kinase). Liu and colleagues
[54] reported that incubating RAW 264.7 murine
macrophage-like cells with LPS leads to increased HMGB1
mRNA expression. LPS-induced upregulation of HMGB1
mRNA expression was blocked by several pharmacological
inhibitors of the JAK/STAT (Janus kinase/signal transducer
and activator of transcription) signaling pathway. Increased
HMGB1 mRNA expression also has been observed in animal
models of acute or chronic inflammation, including collagen-
induced arthritis in rats [55], murine cardiac allograft rejection
[56], and LPS injection in rats pretreated with ethanol [57].
Role of nuclear factor-kappa-B in the regulation of
high-mobility group box 1 secretion
The TLR 4 agonist, LPS, and the cytokines TNF, IFN-γ, and
TWEAK (TNF-like WEAK inducer of apoptosis) have been
shown to induce HMGB1 secretion from macrophages
[12,18,27,53,58]. Nicotine inhibits TNF- or LPS-induced
HMGB1 secretion by RAW 264.7 murine macrophage-like
cells [18]. Nicotine fails to inhibit LPS-induced p38, JNK, or
ERK1/2 MAPK activation in RAW 264.7 cells, but nicotine
does inhibit LPS-induced nuclear factor-kappa-B (NF-κB)-
dependent transcriptional activity [18]. These data have been
interpreted as indicating that TNF- or LPS-induced HMGB1
secretion is mediated, at least in part, via activation of NF-κB,
but signaling via the three main MAPK cascades is not
important [18].
Other data argue against an important role for NF-κB-
dependent signaling. In a study of TNF- or IFN-γ-stimulated
THP-1 cells, Kalinina and colleagues [53] reported that
HMGB1 secretion is not inhibited by the NF-κB inhibitor, iso-
helanin. Similarly, Killeen and colleagues [59] showed that
treating RAW 264.7 cells with PDTC (pyrollidine diothio-
carbamate), SN50 (amino acid sequence AAVALLPAVLLA-
LLAPVQRKRQKLMP), or 5-(thien-3-yl)-3-aminothiophene-2-
carboxamide (SC-514) blocks LPS-induced NF-κB DNA
binding but fails to inhibit LPS-induced HMGB1 secretion.
Receptors for high-mobility group box 1
To date, four transmembrane proteins have been identified as
potential cellular receptors for HMGB1. These proteins are
the Receptor for Advanced Glycation End products (RAGE),
TLR2, TLR4, and syndecan-1 (CD138). It is conceivable,
however, that other cell-surface receptors or even intracellular
receptors participate in HMGB1-mediated cellular activation
(at least in certain cell types). The intracellular protein, TLR9,
also may function as a receptor for HMGB1.
RAGE, a member of the immunoglobulin superfamily of
proteins, is activated by a wide variety of ligands, including
products of the non-enzymatic oxidation of glucose (Advanced
Glycation End products [AGEs]) [60], the amyloid-β peptide
cleavage product of β-amyloid precursor protein [61], and the
S100/calgranulin family of proinflammatory cytokine-like
mediators [62]. HMGB1 also binds to RAGE with high affinity
[63,64], and some of the proinflammatory effects of HMGB1
appear to be mediated by binding of HMGB1 to RAGE
[15,65-67].
The recognition that HMGB1 is capable of activating
RAGE-dependent signaling was prompted by a series of
publications by Rauvala and Pihlaskari [68]. In 1987, they
identified a 27- to 30-kDa heparin-binding protein that
promotes neurite outgrowth in rat brain neurons. Subse-
quently, this research group cloned this protein from a
cDNA library constructed from rat brain mRNA [69]. The
protein, which was called amphoterin because of its
positively charged N-terminal region and negatively charged
C-terminal domain, was shown to have the same primary
amino acid sequence as HMGB1 [69]. Amphoterin/
HMGB1 was shown to be localized in the cytoplasm and
filopodia of neurons [69].
During the course of tissue surveys to assess RAGE
distribution in vivo, it became evident that expression of the
receptor occurs in early development, especially in the central
nervous system where AGEs, the presumed primary ligands
for RAGE, are unlikely to be present. Accordingly, these
Available online http://ccforum.com/content/11/5/229investigators entertained the hypothesis that AGEs might be
accidental ligands for a receptor that has other functions.
Toward this end, they sought to define putative natural
ligands for RAGE. Starting with homogenates prepared from
bovine lung tissue, protein fractions obtained using a heparin-
Sepharose column were evaluated for RAGE-binding activity.
Ultimately, two polypeptides (molecular masses of 12 and
23 kDa) were identified. The 23-kDa polypeptide was
identified as amphoterin/HMGB1 [63]. Moreover, authentic
amphoterin/HMGB1 was shown to bind to RAGE with high
affinity [63]. Subsequently, it was shown that amphoterin
induces neurite outgrowth in neuroblastoma cells transfected
with a plasmid encoding RAGE but not in cells transfected
with a plasmid encoding a mutant RAGE missing the
intracytoplasmic portion of the receptor [70].
More recently, the pathogen-associated molecular pattern
(PAMP) receptors, TLR2 [71-73] and TLR4 [71-76], also
have been identified as HMGB1 receptors. Nevertheless, a
number of studies have shown that treatment of various cell
types with anti-RAGE antibodies inhibits HMGB1-mediated
effects by 50% to 100% [15,31,77,78].
Since key receptors for HMGB1, such as TLR2 and TLR4,
are localized to the apical surface of enteroyctes [71,79], the
observation that HMGB1 is secreted apically by intestinal
epithelial cells supports the idea that release of this protein
might serve an autocrine role to amplify the activation of
enterocytes by other factors. This notion is supported by our
previously reported observation that HMGB1 promotes
activation of NK-κB in Caco-2 cells and also increases the
permeability of Caco-2 monolayers [15]. To specifically test
this hypothesis, Liu and colleagues [33] stimulated Caco-2
monolayers in the absence or presence of a polyclonal
neutralizing anti-HMGB1 antibody added to the apical compart-
ment of Transwell chambers. Treatment with anti-HMGB1 anti-
body significantly blunted the development of hyperpermeability
[33]. Thus, secretion of HMGB1 may be an important positive
feedback phenomenon that promotes the development of
intestinal epithelial barrier dysfunction due to inflammation.
Recently, it has become apparent that highly purified HMGB1
has only minimal cytokine-like activity in vitro, whereas
Escherichia coli-derived recombinant HMGB1, presumably
contaminated with trace amounts of various microbial
products, is more effective at triggering TNF secretion by
cultured macrophages [80,81]. Since HMGB1 tends to
avidly bind bacterial products and DNA, it is possible that the
proinflammatory effects of HMGB1 are mediated not by the
pure protein per se, but rather by complexes formed when the
protein interacts with other proinflammatory substances [82].
This notion is supported by findings reported by Tian and
colleagues [82], who showed that although HMGB1 binds to
a RAGE-like man-made fusion protein (RAGE-Fc), binding is
much better when HMGB1 is complexed with CpG-rich
oligodeoxynucleotides.
TLR9 is a PAMP receptor that is localized within cells in the
endoplasmic reticulum and endosomal compartments
[83,84]. TLR9 recognizes methylated (bacterial) or
unmethylated (eukaryotic) CpG oligodeoxynucleotides [85].
Tian and colleagues [82] have presented data indicating that
complexes of RAGE, CpG-rich oligodeoxynucleotides, and
HMGB1 are transported into cells. These complexes are
localized within an endosomal compartment and are
physically associated with TLR9. Thus, TLR9 may be another
‘HMGB1 receptor,’ at least when HMGB1 is complexed with
CpG-rich oligodeoxynucleotides and RAGE.
High-mobility group box 1 as an inflammatory mediator
implicated in the pathogenesis of critical illness
Circulating concentrations of HMGB1 are increased in
rodent models of sepsis [12,13,19,86-88] or hemorrhagic
shock [75,89]. Furthermore, treatment with anti-HMGB1
neutralizing antibodies has been shown to ameliorate organ
dysfunction and/or improve survival in rodent models of
sepsis [12,13,87], hemorrhagic shock [89,90], acute
pancreatitis [91], and hepatic ischemia/reperfusion injury
[74]. Similarly, drugs that block HMGB1 secretion have been
shown to improve survival and/or ameliorate organ dys-
function in mice subjected to cecal ligation and perforation to
induce sepsis [18,19,92]. Finally, administration of authentic
HMGB1 (or the B box fragment of the protein) has been
shown to induce lethality and/or induce organ damage in
experimental animals [12,15,93]. Thus, HMGB1 appears to
fulfill a modern version of Koch’s postulates for being a
mediator of various forms of acute illness.
Wang and colleagues [12] reported that circulating levels of
HMGB1 are increased in patients with severe sepsis,
particularly among patients with a lethal form of the
syndrome. Similar findings were reported by Hatada and
colleagues [94], who measured plasma immunoreactive
HMGB1 levels in patients with proven or suspected
disseminated intravascular coagulation (DIC) by means of an
enzyme-linked immunosorbent assay (ELISA) system. In that
study, circulating concentrations of HMGB1 were below the
detection limit in normal subjects but were moderately
elevated in patients with infectious diseases, cancer, and
trauma. DIC was associated with even greater plasma
HMGB1 levels, and the highest HMGB1 levels were
detected in patients with organ failure and nonsurvivors.
Other investigators, studying patients with infections and/or
sepsis, have obtained qualitatively different findings. For
example, Gaïni and colleagues [95] reported that circulating
HMGB1 levels are increased (relative to healthy controls) in
intensive care unit (ICU) patients with infections, sepsis, or
severe sepsis (that is, sepsis with organ dysfunction). In that
study, HMGB1 levels were measured by means of a
commercially available ELISA kit. Importantly, these authors
found that HMGB1 levels failed to discriminate between ICU
patients with infections and those without infections. Thus, in
Critical Care    Vol 11 No 5 Fink
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appeared to be more of an indicator of ‘sickness’ rather than
a marker of infection.
Somewhat similar findings were reported by Sunden-
Cullberg and colleagues [96], who detected persistently high
serum levels of HMGB1 in patients with sepsis or septic
shock but found no predictable correlation between HMGB1
concentration and severity of infection. Similarly, in a
prospective study of patients with community-acquired
pneumonia, Angus and colleagues [97] found that plasma
HMGB1 concentrations remained elevated throughout the
hospital course and did not differ between those with and
without severe sepsis. In that study, HMGB1 concentrations
were slightly (and statistically significantly) higher in
nonsurvivors than survivors [97]. Remarkably, half of the
patients who were alive at 90-day follow-up had HMGB1
concentrations greater than three times the upper 95th
percentile of the range for normal controls.
Thus, in our current state of knowledge, we must conclude
that even though HMGB1 is an important mediator of lethal
sepsis in mice and circulating levels of HMGB1 are elevated
in septic humans, there is at best a weak relationship between
the magnitude of ‘HMGB1-emia’ and clinical prognosis. The
story — at least as it stands right now — is indeed puzzling.
High circulating levels of HMGB1 also have been detected in
patients with hemorrhagic shock and/or trauma. Ombrellino
and colleagues [98] described a patient with high circulating
levels of HMGB1 following an episode of hemorrhagic shock.
This finding was confirmed by Yang and colleagues [90], who
showed that circulating HMGB1 levels are significantly
greater in victims of trauma with hemorrhagic shock than
those measured in normal volunteers. High circulating levels
of HMGB1 also have been detected during the first few days
after a major surgical procedure (esophagectomy) [99].
Plasma or serum HMGB1 levels are increased in patients
with acute coronary syndrome or cerebral vascular ischemia
(transient ischemic attack or cerebral vascular accident)
[100], human immunodeficiency virus infection [101],
multiple organ failure associated with critical illness [94],
acute lung injury [102], and severe acute pancreatitis [103].
All of the available clinical data regarding HMGB1 levels in
plasma or serum in patients with various forms of acute or
chronic illness have been obtained by measuring immuno-
reactive levels of the protein. Unfortunately, detecting
HMGB1 by ELISA or Western blot assay fails to provide
information about the functional activity of the protein. It is
possible that the circulating form of HMGB1 changes over
time. For example, in the first 48 hours or so after the onset of
an acute infection, HMGB1 might be present as a pro-
inflammatory mediator, whereas later on the protein might be
biologically inactive (or even, potentially, anti-inflammatory).
Clearly, additional clinical studies that seek to correlate
immunoreactive protein levels with HMGB1-mediated
biological responses are needed.
Therapeutic agents targeting high-mobility group box 1
As yet, of course, no anti-HMGB1 therapeutic is available for
clinical administration to humans. Nevertheless, a number of
agents have been shown to be capable of blocking HMGB1
secretion by immunostimulated cells, including various
nicotinic cholinergic agonists [18,104]; stearoyl lysophos-
phatidylcholine [105]; ethyl pyruvate [19]; the serine protease
inhibitor, nafamostat mesilate [86]; several steroid-like
pigments (tanshinone I, tanshinone IIA, and cryptotanshinone)
derived from a Chinese medicinal herb, danshen (Salvia
miltiorrhiza) [92]; and the diuretic, ethacrynic acid, as well as
other drugs that are known to be ‘phase 2 enzyme’ inducers
[59]. Some of these pharmacological agents, as well as
various polyclonal neutralizing anti-HMGB1 antibodies, have
been shown to ameliorate organ dysfunction and/or improve
survival in various animal models of critical illness (see
above). Because the HMGB1-as-cytokine story is still less
than a decade old, it probably will be several more years
before any of these approaches for targeting HMGB1 will be
tested in a proof-of-principle trial in human patients. However,
because HMGB1 is such an attractive drug target, it seems
likely that such trials eventually will be performed.
Additionally, it is possible that approaches such as using
hemoperfusion through a column packed with the LPS-
binding agent, polymyxin B [106,107], can indirectly
decrease circulating levels of HMGB1 by removing the
upstream stimulus for secretion of the protein.
Conclusion
One of the most important discoveries in the field of
immunology during the past few years was the recognition
that HMGB1 is not only a DNA-binding protein but also a
proinflammatory cytokine-like protein that fulfills ‘Koch’s
postulates’ as a mediator of sepsis-induced lethality (at least in
rodents). Because HMGB1 is released relatively late in the
inflammatory cascade, this protein is potentially quite attractive
as a novel target for new therapeutic agents designed to
improve outcome for patients with sepsis or other forms of
critical illness. By the same token, delineating the precise role
of HMGB1 in the pathogenesis of sepsis or other acute and
chronic inflammatory conditions has proven to be exceedingly
complicated, and we probably are quite a few years away from
knowing whether anti-HMGB1 therapeutic agents will be
beneficial for treating human diseases.
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